Open AccessAtorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial
Author(s) -
Sean P. Polster,
Agnieszka Stadnik,
Amy Akers,
Ying Cao,
Gregory A. Christoforidis,
Maged D Fam,
Kelly D. Flemming,
Romuald Girard,
Nicholas Hobson,
James I. Koenig,
Janne Koskimäki,
Karen Lane,
James K. Liao,
Cornelia Lee,
Seán B. Lyne,
Nichol McBee,
Leslie Morrison,
Kristina Piedad,
Robert Shenkar,
Matthew J. Sorrentino,
Richard E. Thompson,
Kevin J. Whitehead,
Hussein A. Zeineddine,
Daniel F. Hanley,
Issam A. Awad
Publication year - 2018
Publication title -
neurosurgery/neurosurgery online
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.455
H-Index - 198
eISSN - 1081-1281
pISSN - 0148-396X
DOI - 10.1093/neuros/nyy539
Subject(s) - medicine , atorvastatin , placebo , clinical trial , clinical endpoint , randomized controlled trial , adverse effect , magnetic resonance imaging , dosing , radiology , pathology , alternative medicine
More than a million Americans harbor a cerebral cavernous angioma (CA), and those who suffer a prior symptomatic hemorrhage have an exceptionally high rebleeding risk. Preclinical studies show that atorvastatin blunts CA lesion development and hemorrhage through inhibiting RhoA kinase (ROCK), suggesting it may confer a therapeutic benefit.